In the article titled “Serum Procalcitonin Levels in Acute Encephalopathy with Biphasic Seizures and Late Reduced Diffusion” [1], there are errors that should be updated as follows: (1)In Abstract, () should be (), () should be (), and (79% and 100%) should be (100% and 80%)(2)In Section 3.2 in Results, “a sensitivity of 79% and a specificity of 100%” should be “a sensitivity of 100% and specificity of 80%”(3)The figures’ and tables’ captions are incomplete. They should be updated as follows:
Figure 1 PCT/CRP ratio in each disease group. AESD: acute encephalopathy with biphasic seizures and late reduced diffusion; CRP: C-reactive protein; FS: febrile seizures; PCT: procalcitonin; SIRS: systemic inflammatory response syndrome. PCT/CRP ratio = PCT level (ng/mL)/CRP level (mg/dL). Data for the FS and AESD groups are from this study; other data is from Nakanishi et al.
Figure 2 PCT/CRP ratio in FS and AESD. AESD: acute encephalopathy with biphasic seizures and late reduced diffusion; CRP: C-reactive protein; FS, febrile seizures; PCT: procalcitonin. .
Figure 3 Time course of PCT and CRP after onset in AESD. CRP: C-reactive protein; mPSL pulse: methyl prednisolone pulse therapy; PCT: procalcitonin. Follow-up after diagnosis of acute encephalopathy with biphasic seizures and late reduced diffusion and start of intervention. Data are presented as the .
Table 1 Patient characteristics of AESD and FS. AESD: acute encephalopathy with biphasic seizures and late reduced diffusion; FS: febrile seizures; HHV-6: human herpesvirus-6; hMPV: human metapneumovirus. All AESD specimens were subjected to blood culture, and results were all negative.
Table 2 PCT, CRP, and inflammatory cytokine of AESD and FS. AESD: acute encephalopathy with biphasic seizures and late reduced diffusion; CRP: C-reactive protein; FS: febrile seizures; PCT: procalcitonin. Data are presented as the . The ratio was calculated using a CRP value of 0.15 when it is below 0.15.